During the corresponding time, Alnylam Pharmaceuticals Inc recorded a revenue increase by 66.86 % year on year, sequentially revenue grew by 10.6 %. While revenue at the Alnylam Pharmaceuticals Inc 's corporate clients
Alnylam Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company serves customers involved in government price reporting and healthcare programs, including those related to off-label promotion claims. It operates under regulatory oversight affecting pharmaceutical manufacturers, requiring compliance with federal and state fraud and abuse laws, the Anti-Kickback Statute, and the U.S. Foreign Corrupt Practices Act. Its markets include government healthcare programs such as Medicare and Medicaid, private health insurance, and non-U.S. jurisdictions subject to anti-bribery laws. Pharmaceutical manufacturers must adhere to various disclosure and reporting requirements to government agencies, including the FDA. The company is also subject to potential impacts from changes in legislation and FDA regulations concerning the approval, manufacturing, and marketing of drug products.
In a significant advancement in the treatment of uncontrolled hypertension, Genentech, a member of the Roche Group, and Alnylam Pharmaceuticals have announced their decision to initiate a Phase III cardiovascular outcomes trial (CVOT) for zilebesiran, an innovative RNA interference (RNAi) therapeutic. This development follows encouraging results from the KARDIA Phase II program, which assessed the drug s efficacy and safety in earlier studies.Uncontrolled hypertension, or high blood pressure that is not adequately managed through traditional treatments, poses a risk of major adverse cardiovascular events, including heart attack, stroke, and kidney damage. Currently, management options generally include lifes...
CAMBRIDGE, Massachusetts In a remarkable stride toward revolutionizing healthcare, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is setting the stage to unveil groundbreaking innovations at the forthcoming European Society of Cardiology (ESC) Congress 2025. This prestigious event, scheduled from August 29 to September 1 in Madrid, Spain, will serve as the platform for Alnylam to showcase transformative data highlighting the potential of RNA interference (RNAi) therapeutics in the treatment of cardiovascular diseases.As the frontrunner in the realm of RNAi therapeutics, Alnylam is pioneering an era where genetic science meets clinical application, aiming to address some of the most formidable challenges in m...
Alnylam Pharmaceuticals Breakthrough Approval: AMVUTTRA for ATTR-CM Garners FDA Nod Alnylam Pharmaceuticals Leads Innovation in RNAi Therapeutics with AMVUTTRA and Promising Research on Nucresiran Alnylam Pharmaceuticals, Inc. a pioneer in the development of RNA interference (RNAi) therapeutics, has announced the U.S. Food and Drug Administration s (FDA) approval of their supplemental New Drug Application (sNDA) for AMVUTTRA (vutrisiran). This significant milestone underscores Alnylam s continued innovation in addressing the cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM), a condition with profound impacts on patients cardiovascular health.ATTR amyloidosis is a systemic conditi...
The world of pharmaceutical science is continually evolving, bringing promising advancements that have the potential to transform patient care. In this light, Alnylam Pharmaceuticals has announced a significant milestone in the development and potential treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). This article aims to analyze the recent announcement of the U.S. Food and Drug Administration s (FDA) acceptance of the supplemental New Drug Application (sNDA) for vutrisiran, highlighting its implications within the medical and scientific communities. Background on ATTR Amyloidosis with Cardiomyopathy ATTR amyloidosis with cardiomyopathy is a progressive and life-threatening condition characterize...
Alnylam Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company serves customers involved in government price reporting and healthcare programs, including those related to off-label promotion claims. It operates under regulatory oversight affecting pharmaceutical manufacturers, requiring compliance with federal and state fraud and abuse laws, the Anti-Kickback Statute, and the U.S. Foreign Corrupt Practices Act. Its markets include government healthcare programs such as Medicare and Medicaid, private health insurance, and non-U.S. jurisdictions subject to anti-bribery laws. Pharmaceutical manufacturers must adhere to various disclosure and reporting requirements to government agencies, including the FDA. The company is also subject to potential impacts from changes in legislation and FDA regulations concerning the approval, manufacturing, and marketing of drug products.
Sources:
Alnylam Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Alnylam Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Alnylam Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
80.26 %